Positive News SentimentPositive NewsNASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis $4.36 -0.16 (-3.54%) Closing price 04:00 PM EasternExtended Trading$4.38 +0.01 (+0.34%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Abeona Therapeutics Stock (NASDAQ:ABEO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Abeona Therapeutics alerts:Sign Up Key Stats Today's Range$4.28▼$4.5150-Day Range$4.36▼$7.4652-Week Range$4.00▼$7.65Volume1.77 million shsAverage Volume1.41 million shsMarket Capitalization$249.30 millionP/E RatioN/ADividend YieldN/APrice Target$21.00Consensus RatingModerate Buy Company Overview Abeona Therapeutics Inc. is a biotechnology company focused on developing and commercializing cell and gene therapies for serious diseases. The company’s primary focus is regenerative medicine, with an emphasis on treatments that address rare genetic disorders and conditions involving damaged or absent tissue. Abeona’s lead product, ZEVASKYN (prademagene zamikeracel, formerly EB-101), is an autologous, gene-corrected cell therapy for wounds associated with recessive dystrophic epidermolysis bullosa (RDEB). The treatment uses a patient’s own skin cells, which are genetically modified to produce functional type VII collagen and expanded into replacement skin grafts for chronic wounds. The U.S. Food and Drug Administration approved ZEVASKYN in 2025 for eligible adult and pediatric patients with RDEB. Abeona is based in the United States and has developed its therapies through U.S. research, manufacturing, and regulatory operations. The company continues to focus on advancing specialized cell and gene therapies for patients with limited treatment options.AI Generated. May Contain Errors. Read More Abeona Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreABEO MarketRank™: 3.047481257395 of 5 starsAbeona Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 375th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingAbeona Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAbeona Therapeutics has a consensus price target of $21.00, representing about 381.7% upside from its current price of $4.36.Amount of Analyst CoverageAbeona Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Abeona Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($0.88) to ($0.14) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -4.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Abeona Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted31.78% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 11.57, which indicates bearish sentiment.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 7.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. News and Social Media4.1 / 5News Sentiment1.60 News SentimentAbeona Therapeutics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Abeona Therapeutics this week, compared to 5 articles on an average week.Search Interest7 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days.MarketBeat Follows2 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $306,160.00 in company stock.Percentage Held by Insiders7.10% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Abeona Therapeutics' insider trading history. Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABEO Stock News HeadlinesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOOctober 6, 2026 | globenewswire.comAbeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's visibility into consumer bank transactions. A pilot program is reportedly already underway, with wider rollout at major banks possibly beginning this summer. Martin D. Weiss, PhD, founder of Weiss Ratings, breaks down what the document says and what steps account holders might consider.October 14 at 1:00 AM | Weiss Ratings (Ad)Il SVP di Abeona Therapeutics vende azioni per $34.681September 30, 2026 | it.investing.comIl CFO di Abeona Therapeutics Joseph Vazzano vende azioni per $47.385September 30, 2026 | it.investing.comInsider Selling: Abeona Therapeutics (NASDAQ:ABEO) Insider Sells 4,902 Shares of StockSeptember 30, 2026 | insidertrades.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOSeptember 29, 2026 | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abeona Therapeutics Inc. - ABEOSeptember 24, 2026 | prnewswire.comSee More Headlines ABEO Stock Analysis - Frequently Asked Questions How have ABEO shares performed this year? Abeona Therapeutics' stock was trading at $5.27 at the beginning of 2026. Since then, ABEO stock has decreased by 17.3% and is now trading at $4.36. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc. (NASDAQ:ABEO) posted its quarterly earnings results on Thursday, August, 13th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by $0.12. The biopharmaceutical company earned $11.38 million during the quarter, compared to analyst estimates of $12.24 million. Read the conference call transcript. When did Abeona Therapeutics' stock split? Abeona Therapeutics shares reverse split before market open on Tuesday, July 5th 2022.The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Abeona Therapeutics investors own include Alibaba Group (BABA), Advanced Micro Devices (AMD), Tesla (TSLA), Bristol Myers Squibb (BMY), NIO (NIO), NVIDIA (NVDA) and Micron Technology (MU). Company Calendar Last Earnings8/13/2026Today10/14/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, ABEO's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CIK318306 Webwww.abeonatherapeutics.com Phone(646) 813-4701Fax214-905-5101Employees226Year Founded2013Price Target and Rating Average Price Target for Abeona Therapeutics$21.00 High Price Target$30.00 Low Price Target$17.00 Potential Upside/Downside+381.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$71.18 million Net MarginsN/A Pretax Margin-306.81% Return on Equity-41.69% Return on Assets-30.36% Debt Debt-to-Equity Ratio0.01 Current Ratio6.63 Quick Ratio6.40 Sales & Book Value Annual Sales$5.82 million Price / Sales42.84 Cash FlowN/A Price / Cash FlowN/A Book Value$2.94 per share Price / Book1.48Miscellaneous Outstanding Shares57,180,000Free Float53,124,000Market Cap$249.30 million OptionableOptionable Beta1.31 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ABEO) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredWhy Some AI Stocks Already Surged Over 300 PercentJason Bodner's system flagged Nvidia before a 7000 percent run, Super Micro Computer before a 2600 percent run...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredElon pays this company. Every time.Every Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredUrgent: Invest In ‘Elon’s iPhone’ Before July 22ndEarly Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredBlackRock is all over this (are you?)BlackRock's new fund hit $2.8 billion in under three months. JPMorgan is now running $2 billion a day through ...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Abeona Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ABEO Stock Alerts